Objectives. To investigate the effects of precursor chemical regulation aimed at reducing cocaine production on cocaine-related maternal and newborn hospital stays in the United States.
I
n 2012, there were 65 855 maternal and 30 653 neonatal stays related to substances, including cocaine, in the United States. 1 Cocaine exposure is associated with placental complications, premature delivery, and poor fetal growth. 2, 3 Fortunately, in the past decade, there was a substantial decline in the number of neonatal and maternal hospital stays related to cocaine exposure. The Agency for Healthcare Research and Quality reported that the rate of neonatal and maternal hospital stays related to cocaine declined by 59.7% and 50.5%, respectively, between 2006 and 2012. 1 Pan and Yi found that between 1999 and 2008, the prevalence of neonates and mothers affected by cocaine declined by 51.3% and 38.8%, respectively. 4 This surveillance data are encouraging, but do not explain why there was an improvement in these outcomes. We propose that federal regulation of sodium permanganate, a precursor chemical needed to produce cocaine, provides a reasonable hypothesis. Previous literature on this topic is sparse. Cunningham et al. found that federal regulation of sodium permanganate led to statistically significant decreases in cocaine seizures (-22%) and purity (-35%), and a large increase in price (+100%). 5 Cunningham et al. found that the number of past-year cocaine users declined by 32% as a result of the regulation. 6 Research findings are consistent with the US Drug Enforcement Administration's analysis that the US market experienced an "unprecedented drop" in cocaine supply before early 2007. 7(p3) However, the impact on cocaine-related health outcomes has yet to be examined. We tested the hypothesis that federal precursor regulation in December 2006 had an immediate impact on 2 maternal and child health outcomes: cocaine-related maternal and neonatal hospital stays in the United States.
METHODS
We evaluated the effect of the December 2006 change in federal precursor regulation on cocaine-related maternal and neonatal inpatient hospital stays ("stays") by using a quasi-experimental interrupted time series design. We analyzed monthly counts of maternal and neonatal stays from January 2002 through December 2013. Because of the federal nature of the regulation, no comparable control group is available. To confound an abrupt change immediately after regulation, confounders would also need to change abruptly around the time of regulation. Confounders, however, tend to change slowly over time and are accounted for by comparing to the baseline trend in maternal and neonatal stays. To be conservative, we controlled for (1) gestational age, (2) age of the mother, (3) maternal race, (4) total number of live births, and (5) alcohol-related stays.
Data
We examined monthly stays related to cocaine use from 2002 to 2013 (most recent available data) by using discharge data from the National Inpatient Sample and Nationwide Inpatient Sample, Health Care Cost and Utilization Project, and Agency for Healthcare Quality and Research. Monthly time series were estimated for all outcomes and covariates and then merged at the month level.
Using a National Inpatient Sample and Nationwide Inpatient Sample precalculated field, we defined neonatal stays as records with neonatal diagnoses and age younger than 1 year. 1 We confirmed the age-range validity of this indicator by finding that less than 0.5% of these newborns were older than 28 days. We identified cocaine exposure with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 8 diagnosis code of 760.75 (cocaine affecting fetus or newborn via placenta or breast milk) in any diagnosis field.
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We defined a maternal stay as a record with maternal diagnoses or procedures and age between 15 and 45 years. 1 We identified maternal stays related to cocaine dependence, abuse, or poisoning with the ICD-9-CM diagnosis codes of 304.20 to 304.22, 305.60 to 305.62, and 970.81, respectively, in any diagnosis field. We calculated our covariates directly from birth certificate data available from National Vital Statistics (https://www.cdc.gov/nchs/ data_access/vitalstatsonline.htm).
Statistical Analysis
We analyzed unadjusted and adjusted segmented regressions of the following form: 
RESULTS
Over the study period, the prevalence of most baseline (years 2002-2006) characteristics remained stable, although some changes were significant at the 95% confidence level for both maternal and neonatal stays (data not shown). Stays for those aged 25 to 34 years increased from 54.4% at baseline to 60.2% in the 2010 to 2013 period, with a concurrent decrease in stays for the youngest (aged < 20 years) and oldest (aged ‡ 35 years) populations. In addition, the percentage of stays paid for by Medicaid increased from 70.6% to 74.7% between these periods. For neonatal stays, the total mean length of stay increased from 8.7 days at baseline to 11.2 days in the 2010 to 2013 period. In addition, there was an increase in reporting of severe illnesses such as respiratory distress, difficulty feeding, and small for gestational age. There was no increase in percentage of infants reported premature or low birth weight. As noted in the maternal population, there was a similar increase in stays paid for by Medicaid in the neonatal population, from 74.7% at baseline to 82.1% in the 2010 to 2013 period. Diagnosis codes from ICD-9-CM can be provided upon request. Figure 1 shows the monthly trends in cocaine-related stays. The outcomes reached study period maximums in September and October 2006 at 1922 and 984 stays, respectively. Following the regulation change, the number of monthly cocaine-related maternal and neonatal stays decreased by 221 (P = .014) and 128 (P = .016) stays, respectively. We observed a further reduction in per-month maternal and neonatal stays of 18 (P < .001) and 8 stays (P < .001), respectively. These results were robust to the control of additional covariates (Table A, available as a supplement to the online version of this article at http://www.ajph.org).
DISCUSSION
Federal regulation of an essential cocaine precursor (sodium permanganate) was associated with both an immediate and sustained change in cocaine-related maternal and neonatal stays. These findings are consistent with behavioral economic research showing that pregnant women will decrease cocaine consumption when the price per gram increases. 9 Thus, our quasi-experimental results, triangulated with simultaneous changes in several cocaine-related indicators from multiple, independent sources, suggest that this intervention played an important role in this aspect of maternal and child health in the United States.
We cannot entirely attribute the decline to federal regulation alone. On the supply side, in Colombia, coca plant eradication efforts intensified from 2006 to 2011 resulting in production declines and movement of cocaine production to other countries. 10 On the other hand, Cunningham et al. argued that coca cultivation actually increased in 2007 and 2008 relative to 2006. 6 We could not find evidence of a public health intervention or changes in hospital coding practice that could otherwise explain the magnitude of this decline. The use of diagnostic codes likely underestimates the true number of cases. By using live births as a covariate, we controlled for the downward pressure that the economic recession had on all births.
Despite the positive impact associated with this regulation, we do note the US Drug Enforcement Administration's recent concern about increasing cocaine availability in the United States and additional evidence that population health measures are responding.
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For example, cocaine-caused deaths increased by 62% from 2010 to 2015 after reaching a 9-year low in 2010.
12 Likewise, the annual prevalence of cocaine use among young adults (aged 19-28 years) reached a low of 3.9% in 2013 then increased significantly for 2 consecutive years with 5.7% reported in 2015. 13 This resurgence may be associated with the increasing polysubstance nature of the current opioid and heroin epidemic.
This study contributes to a new body of evidence showing large public health benefits of federal precursor regulation aimed at reducing cocaine availability in the United States. 
